Feature | May 17, 2012| Dave Fornell

Research Shows Brief Ablation of Rotor Center May Cure AFib Without Long Procedures

Data may show new direction for more effective, faster catheter ablation in atrial fibrillation patients

An illustration of the FIRM mapping technique and how its pin-point of an AFib rotor correlates on an EP mapping system.

The current standard-of-care for catheter ablation of atrial fibrillation (AFib) patients includes up to six-hour long procedures with success rates that all electrophysiologists say can be improved. A possible break-through advance in ablation technology may help reduce procedure times by 80 percent, reduce damage to the heart and increase the effectiveness of ablation therapy.

A new electromapping technique can better visualize the rotor (similar to the eye of a hurricane) around which electrical activity called initiating spirals rotate. Using this map, the electrophysiologist (EP) can position an ablation catheter on the rotor center and see immediately the results of the treatment. By using this targeted technique, in some cases a single ablation can  terminate the AFib and restore the heart to normal rhythm. In conventional treatment, hours of ablation over a large area of the heart is needed to achieve a similar result.

“Incredible! This is going to turn the AFib world upside down,” said Warren "Sonny" Jackman, M.D., FHRS, George Lynn Cross research professor, senior scientific advisor, Heart Rhythm Institute, University of Oklahoma Health Sciences Center, Oklahoma City.

He said FIRM might be a big leap forward and be a paradigm shift in how AFib ablations are performed to achieve more efficiency and better patient outcomes.

The technique was presented at the Heart Rhythm Society (HRS) 2012 scientific sessions May 9 in Boston. Sanjiv M. Narayan, M.D., Ph.D., FHRS, associate professor of medicine in residence, co-director, EP fellowship training program, director, VA EP program, University of California San Diego School of Medicine, VA Medical Centerpresented his research on targeted ablation at sources alone using focal impulse and rotor modulation (FIRM).  He said the technique acutely terminates or slows human AFib.

Narayan said recent studies have shown that localized electrical rotors and focal beats may sustain human AFib. His team hypothesized that brief ablation (?10 min) of these sources could terminate AFib without pulmonary vein ablation.

In 51 AFib patients (63±10 years; left atrial, LA size 49±8 mm; 41 persistent), they recorded AFib using a 64-pole basket mapping catheters in both atria. Wave similarity and Hilbert analyses were used to detect AFib rotors or focal beats. This was visualized on a flattened, 2-D, “panoramic” electromap showing a cine loop of the electrical signal motion. This allows much easier visualization of rotors. Current technology requires EPs to look at numerous individual points on an electrogram and reconstruct the electrical motion in their minds. However, the FIRM map takes the guesswork out of visualization and more clearly shows the location of a rotor.

“You look at the electrograms and you cannot reconstruct this in your head,” Jackman said. “Based on an electrogram I could never have done that.”

Narayan’s team used FIRM ablation applied for less than 10 minutes/source to terminate or slow the AFib prior to pulmonary vein isolation. Patient-specific FIRM maps revealed rotors or focal beats in 50 of the 51 patients. The acute endpoint was achieved in 45 of 51 patients (an 88 percent success rate) with no other ablation. AFib terminated in 29 patients (57 percent) in 4.2 minutes. In 16 patients, FIRM slowed AF by 24±10 ms (15±3 percent).

Narayan said ablation at only the center of the rotor using FIRM terminated AFib to sinus rhythm in less than one minute. He explained computational mapping reveals rotors and focal beat drivers in nearly all persistent and paroxysmal AFib patients, where very brief FIRM ablation rapidly terminated or substantially slowed AFib. While the findings are very promising, we said more data is needed to determine how FIRM ablation may optimize procedural time and outcomes from AFib ablation.

The technique does not always work, Narayan said. He said the biggest predictor of failure seems to be if the basket is too big to get into the pulmonary vein, or are not seated properly in the atria, which means some areas are not mapped, giving an incomplete FIRM map. Incomplete seating in the atria can usually been seen under angiography, where the arms of the basket are not deformed, because they are not contacting the walls of the heart.

Narayan received a standing ovation at the conclusion of his presentation and for 40 minutes following the session was surrounded by doctors who wanted to learn more about the FIRM technique.

 

Related Content

News | Heart Failure| August 28, 2015
August 28, 2015 — BioControl Medical said it has completed enrollment in its INOVATE-HF (INcrease Of VAgal TonE in He
BioSig Technologies, research agreement, UCLA, Pure EP System, EP lab, ventricular tachycardia model, VT
Technology | EP Lab| August 20, 2015
BioSig Technologies announced it has signed a sponsored research agreement with the regents of the University of...
Sunshine Heart, COUNTER HF pivotal study, resumes enrollment, C-Pulse, FDA
News | Heart Failure| August 18, 2015
Sunshine Heart Inc. announced an update in late July on its COUNTER HF U.S. pivotal study for the C-Pulse Heart Assist...
Biotronik, BioCONTINUE study, CRT-D, defibrillator, cardiac resynchronization therapy device, heart failure, first replacement
News | Cardiac Resynchronization Therapy Devices (CRT)| August 17, 2015
Biotronik announced that the first patient has been enrolled in the BioCONTINUE clinical trial (BIOtronik study to...
CMS, additional participants, Bundled Payments for Care Improvement initiative, Medicare, eipsodes of care
News | Business| August 17, 2015
The Centers for Medicare & Medicaid Service (CMS) announced that over 2,100 healthcare facilities have agreed to...
Medtronic, Endurant Evo AAA, stent graft system, first European cases
News | Stent Grafts| August 13, 2015
Medtronic plc announced that the first two European patient cases with the Endurant Evo AAA stent graft system were...
zebrafish, iWorx Systems Inc., ZS-200 Zebrafish ECG System, cardiac research
Technology | ECG| August 13, 2015
iWorx Systems Inc., developer of advanced physiology teaching and research instruments and software, has introduced a...
HeartWare, ENDURANCE2 trial, destination therapy, HVAS, HeartWare Ventricular Assist System
News | Ventricular Assist Devices (VAD)| August 11, 2015
HeartWare International Inc. announced that enrollment in the ENDURANCE2 destination therapy clinical trial has been...
Biotronik, BIOGUARD-MI Study, BioMonitor, cardiac arrhythmias, early detection, remote monitoring
News | Implantable Cardiac Monitor (ICM)| August 11, 2015
Biotronik announced the first enrollments in the BIO|GUARD-MI1 study. The study will investigate whether the early...
Overlay Init